Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Lexicon Pharmaceuticals Inc (LXRX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Lexicon's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.540 -0.060    -3.75%
25/04 - Closed. Currency in USD ( Disclaimer )
After Hours
1.550
+0.010
+0.649%
19:59:27 - Real-time Data
  • Volume: 1,638,304
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 1.520 - 1.590
Type:  Equity
Market:  United States
Lexicon 1.540 -0.060 -3.75%

Lexicon Pharmaceuticals Inc Company Profile

 
Get an in-depth profile of Lexicon Pharmaceuticals Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

135

Equity Type

ORD

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Contact Information

Address 2445 Technology Forest Boulevard 11th Floor
The Woodlands, 77381
United States
Phone 281 863 3000
Fax 281 863 8088

Top Executives

Name Age Since Title
Samuel L. Barker 79 2000 Independent Director
Lonnel Coats 57 2014 CEO & Director
Raymond Debbane 67 2007 Independent Chairman of the Board
Judith Lea Swain 74 2007 Independent Director
Christopher J. Sobecki 64 2007 Independent Director
Philippe J. Amouyal 64 2007 Independent Director
Robert J. Lefkowitz 80 2001 Independent Director
Alan Sheffer Nies 86 2003 Chairman of Medical Advisory Board
Diane E. Sullivan 61 2023 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

LXRX Comments

Write your thoughts about Lexicon Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Ngoni Nleya
Ngoni Nleya Jan 27, 2021 13:04
Saved. See Saved Items.
This comment has already been saved in your Saved Items
LXRX great stock for long term investment also Check NAKD it's an amazing opportunity
Ngoni Nleya
Ngoni Nleya Jan 14, 2021 13:32
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Great stock to invest on today going to 150%
Ngoni Nleya
Ngoni Nleya Jan 14, 2021 12:17
Saved. See Saved Items.
This comment has already been saved in your Saved Items
LXRX is on fire its going to 200% today
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email